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both in humans and models. Reference to these studies
are given in Giannattasio’s editorial. Calibration by cuff
sphygmomanometer provides its greatest inaccuracy in
measuring aortic pressure as it does for measuring
upper limb pressure. The article by Davies et al. [1]
would have been more accurately titled ‘Peripheral
blood pressure measurement is as bad as . . . .’.
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We thank doctors O’Rourke and Avolio for their
correspondence regarding our article. Although we are
aware that peripheral blood pressure measurements are
associated with a degree of inaccuracy, this does not
challenge our findings. In our study, we compared
standard peripheral blood pressure measurements with
the SphygmoCor system as calibrated with the same
peripheral blood pressure measurement. Therefore, the
inaccuracies encountered with the peripheral blood
pressure measurement applied equally to the two
techniques under comparison. We found that the
SphygmoCor system actually augmented this inaccu-
racy. We accept that, when applied to invasive data,
the transfer system of the SphygmoCor system is
accurate; however, invasive blood pressure monitoring
is clearly not acceptable in a clinical setting, which is
one of the situations in which this system is promoted
for use. We have clearly shown that, in a clinical
setting, a simple peripheral oscillometric blood pressure
measurement is better than the SphygmoCor system at
estimating ascending aortic blood pressure. Perhaps if
we were to change our title, as doctors O’Rourke and
Avolio suggest, it should be to ‘the SphygmoCor and
peripheral blood pressure measurements are both bad
at estimating ascending aortic pressure, but the Sphyg-
moCor system is worse’.
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The evocative hypothesis on angiogenesis as a major
contributing factor in the pathogenesis of Alzheimer’s
disease by Vagnucci and Li [1] raises a variety of
comments.
First, their hypothesis does not account for the substan-
tial role of hypertension in the pathogenesis of both
vascular and degenerative dementias [2], although
hypertension notably coincides with microvascular rare-
faction rather than proliferation.
Second, the list of various drugs with attributed pre-
ventive effects on Alzheimer’s disease (their Table 1)
is based on the evidence that all drugs, with the
exception of nitrendipine, merely contain at best an
educated guess at their potential. The latter investiga-
tions basically comprise uncontrolled retrospective ob-
servational data sources, and are devoid of ruling out a
host of confounding factors pervading such post-hoc
evaluations [3].
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Of course such crude trends may harbour the potential
for generating attractive hypotheses [1], but a sound
and viable hypothesis should rather rest on infallible
evidence. The latter can only be obtained through
well-controlled, randomized, comparative prospective
trials, of which the authors list one (!) example in their
Table 1, referring to the preventive role of the calcium-
antagonist nitrendipine used in the Systolic Hyper-
tension in Europe (Syst-Eur) trial. Its first report [4]
was followed by a second one 4 years later [5], doubling
the median observation period, as well as the further
incidence of Alzheimer’s disease, and maintaining a
reduction by 50% through active treatment based on
nitrendipine as the main stay of drug therapy.
Such dramatic effects have not been observed in
other prospective trials using several other anti-
hypertensive regimes versus their control arms [6–9].
Apparently blood pressure reduction per se lacks the
potential of preventing hypertension-related (degenera-
tive) dementia, at least past a certain stage. This seems
to justify invoking dihydropyridine-induced calcium-
channel blockade as a specific preventive mechanism in
this regard, although this remains to be tested by direct
comparison between a dihydropyridine calcium antago-
nist and any other current antihypertensive drug(s). For
such a trial, we are urgently seeking the necessary
funding to confirm the above, together with the results
of one convincing experimental study [10].
This brings us to our third exception regarding the
hypothesis by Drs Vagnucci and Li. It ignores the
accumulative evidence regarding the dysregulation of
cerebrocellular calcium homeostasis as a core factor in
the pathogenesis of Alzheimer’s disease [11,12]. This is
not to negate the presence of angiogenesis, although
the latter may well rate as a secondary epiphenomenon.
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